文献速递糖尿病

GRADE研究中胰岛素敏感性与β细胞功能随时间变化对血糖结局的影响:双药治疗的差异疗效

Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy.
PubMed 文献 · Diabetes Care · 2024-01-01

GRADE研究将二甲双胍治疗的2型糖尿病患者随机分配至格列美脲(n=1254)、利拉鲁肽(n=1262)或西格列汀(n=1268)组,平均随访5.0±1.3年。结果显示,胰岛素敏感性和β细胞功能影响所有治疗组的血糖结局,且在西格列汀组对初始HbA1c反应的影响大于格列美脲和利拉鲁肽组。

要点

  • 胰岛素敏感性和β细胞功能影响所有治疗组的HbA1c变化及血糖失败风险。
  • 西格列汀组中胰岛素敏感性和β细胞功能对初始HbA1c下降的影响大于格列美脲和利拉鲁肽组。
  • 不同治疗组对次要结局(HbA1c>7.5%)的影响无差异。

核心结论

  • 胰岛素敏感性和β细胞功能影响治疗结局,与药物分组无关,在西格列汀组中对短期HbA1c反应的影响大于格列美脲和利拉鲁肽组。

研究设计与样本

  • GRADE研究参与者随机接受格列美脲(n=1254)、利拉鲁肽(n=1262)或西格列汀(n=1268)联合基线二甲双胍治疗,平均随访5.0±1.3年。

主要发现

  • 较高的HOMA2-%S与3个月时更大的初始HbA1c下降相关,但与后续HbA1c上升无关。
  • 较高的C肽反应与更大的初始治疗反应和更慢的后续HbA1c上升相关。
  • 较高的HOMA2-%S和C肽反应均与主要结局和次要结局风险降低相关。
  • 西格列汀组中HOMA2-%S和C肽反应对初始HbA1c下降的影响大于格列美脲和利拉鲁肽组(异质性检验P=0.009 HOMA2-%S,P=0.018早期C肽,P=0.001总C肽)。
  • 西格列汀组中HOMA2-%S和C肽反应对主要结局风险的影响大于格列美脲和利拉鲁肽组(P=0.005 HOMA2-%S,P=0.11早期C肽,P=0.025总C肽)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the effects of insulin sensitivity and β-cell function over time on HbA1c and durability of glycemic control in response to dual therapy. RESEARCH DESIGN AND METHODS: GRADE participants were randomized to glimepiride (n = 1,254), liraglutide (n = 1,262), or sitagliptin (n = 1,268) added to baseline metformin and followed for mean ± SD 5.0 ± 1.3 years, with HbA1c assessed quarterly and oral glucose tolerance tests at baseline, 1, 3, and 5 years. We related time-varying insulin sensitivity (HOMA 2 of insulin sensitivity [HOMA2-%S]) and early (0-30 min) and total (0-120 min) C-peptide (CP) responses to changes in HbA1c and glycemic failure (primary outcome HbA1c ≥7% [53 mmol/mol] and secondary outcome HbA1c >7.5% [58 mmol/mol]) and examined differential treatment responses. RESULTS: Higher HOMA2-%S was associated with greater initial HbA1c lowering (3 months) but not subsequent HbA1c rise. Greater CP responses were associated with a greater initial treatment response and slower subsequent HbA1c rise. Higher HOMA2-%S and CP responses were each associated with lower risk of primary and secondary outcomes. These associations differed by treatment. In the sitagliptin group, HOMA2-%S and CP responses had greater impact on initial HbA1c reduction (test of heterogeneity, P = 0.009 HOMA2-%S, P = 0.018 early CP, P = 0.001 total CP) and risk of primary outcome (P = 0.005 HOMA2-%S, P = 0.11 early CP, P = 0.025 total CP) but lesser impact on HbA1c rise (P = 0.175 HOMA2-%S, P = 0.006 early CP, P < 0.001 total CP) in comparisons with the glimepiride and liraglutide groups. There were no differential treatment effects on secondary outcome. CONCLUSIONS: Insulin sensitivity and β-cell function affected treatment outcomes irrespective of drug assignment, with greater impact in the sitagliptin group on initial (short-term) HbA1c response in comparison with the glimepiride and liraglutide groups.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Utzschneider KM, Younes N, Butera NM, et al. Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy. Diabetes Care. 2024. PMID: 38190619. doi:10.2337/dc23-1059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。